Back to discover
Disease

Fibrodysplasia ossificans progressiva

Late-stage therapeutic development
Also known as FOP, Stone Man syndrome, Stone man syndrome, fop+3 more

FOP, Stone Man syndrome, Stone man syndrome, fop, progressive myositis ossificans, progressive ossifying myositis, myositis ossificans progressiva.

11
Clinical trials
3
Associated genes
2
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q3 2027.
  • 1 industry development reported.
Upcoming Milestones
Clinical Milestones3View
Results expected 2
Other updates 1
Industry & Market1View
Activity timeline4

Clinical trials

6 sponsors · 0 new · 0 completed in the last 12 months (net -1)

The current development programme across all trial phases.

Clinical programme
11
All trials
3
Active
4
Late-stage
5
Completed
Late-stage studies

Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva

Phase 3 · Active, not recruiting · Regeneron Pharmaceuticals

A Phase 2/3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study With Open-Label Extension (OLE) to Assess the Efficacy and Safety of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Phase 2/3 · Active, not recruiting · Ashibio Inc

Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit From Palovarotene Therapy.

Phase 3 · Completed · Ipsen

A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

Phase 3 · Completed · Clementia Pharmaceuticals Inc.
Recently completed

Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit From Palovarotene Therapy.

Phase 3 · Completed · Ipsen

A Phase 2, Open-Label Extension, Efficacy and Safety Study of a Retinoic Acid Receptor Gamma (RARγ) Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Phase 2 · Completed · Clementia Pharmaceuticals Inc.

Single-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-6016a After Subcutaneous Injection in Healthy Japanese Subjects

Phase 1 · Completed · Daiichi Sankyo Co., Ltd.

A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

Phase 3 · Completed · Clementia Pharmaceuticals Inc.

A Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Heterotopic Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

Phase 2 · Completed · Regeneron Pharmaceuticals

Associated genes

3 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

ACVR10.82RARG0.52INHBA0.37

Disease biology

2 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Retinoic acid receptor gammavia RARG0.52Inhibin beta A chainvia INHBA0.37

Reference

Authoritative identity, definition & identifiers.

Synonyms

FOP, Stone Man syndrome, Stone man syndrome, fop, progressive myositis ossificans, progressive ossifying myositis, myositis ossificans progressiva

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.